Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 245

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

New pro-resolving n-3 mediators bridge resolution of infectious inflammation to tissue regeneration

Open access
Serhan, Charles N., Chiang, Nan, Dalli, Jesmond·2018·Molecular Aspects of Medicine
DOI 10.1016/j.mam.2017.08.002
Open this paper in CoChat — free account

Abstract

While protective, the acute inflammatory response when uncontrolled can lead to further tissue damage and chronic inflammation that is now widely recognized to play important roles in many commonly occurring diseases, such as cardiovascular disease, neurodegenerative diseases, metabolic syndrome, and many other diseases of significant public health concern. The ideal response to initial challenges of the host is complete resolution of the acute inflammatory response, which is now recognized to be a biosynthetically active process governed by specialized pro-resolving mediators (SPM). These chemically distinct families include lipoxins, resolvins, protectins and maresins that are biosynthesized from essential fatty acids. The biosynthesis and complete stereochemical assignments of the major SPM are established, and new profiling procedures have recently been introduced to document the activation of these pathways in vivo with isolated cells and in human tissues. The active resolution phase leads to tissue regeneration, where we’ve recently identified new molecules that communicate during resolution of inflammation to activate tissue regeneration in model organisms. This review presents an update on the documentation of the roles of SPMs and the biosynthesis and structural elucidation of novel mediators that stimulate tissue regeneration, coined conjugates in tissue regeneration. The identification and actions of the three families, maresin conjugates in tissue regeneration (MCTR), protectin conjugates in tissue regeneration (PCTR), and resolvin conjugates in tissue regeneration (RCTR), are reviewed here. The identification, structural elucidation and the pathways and biosynthesis of these new mediators in tissue regeneration demonstrate the host capacity to protect from collateral tissue damage, stimulate clearance of bacteria and debris, and promote tissue regeneration via endogenous pathways and molecules in the resolution metabolome.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.mam.2017.08.002

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Research works printed but not linked: 167

  1. Arita, 2005, Stereochemical assignment, anti-inflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1, J. Exp. Med., 201, 713, 10.1084/jem.20042031 · DOI · Paper page
  2. Arita, 2007, Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation, J. Immunol., 178, 3912, 10.4049/jimmunol.178.6.3912 · DOI · Paper page
  3. Arnardottir, 2016, Human milk proresolving mediators stimulate resolution of acute inflammation, Mucosal Immunol., 9, 757, 10.1038/mi.2015.99 · DOI
  4. Arnardottir, 2016, Resolvin D3 is dysregulated in arthritis and reduces arthritic inflammation, J. Immunol., 197, 2362, 10.4049/jimmunol.1502268 · DOI
  5. Bailey, 2013, Why US adults use dietary supplements, JAMA Intern Med., 173, 355, 10.1001/jamainternmed.2013.2299 · DOI · Paper page
  6. Balas, 2016, Dihydroxylated E, E,Z-docosatrienes. An overview of their synthesis and biological significance, Prog. Lipid Res., 61, 1, 10.1016/j.plipres.2015.10.002 · DOI
  7. Bandeira-Melo, 2000, Cyclooxygenase-2-derived prostaglandin E2 and lipoxin A4 accelerate resolution of allergic edema in Angiostrongylus costaricensis-infected rats: relationship with concurrent eosinophilia, J. Immunol., 164, 1029, 10.4049/jimmunol.164.2.1029 · DOI
  8. Bang, 2010, Resolvin D1 attenuates activation of sensory transient receptor potential channels leading to multiple anti-nociception, Br. J. Pharmacol., 161, 707, 10.1111/j.1476-5381.2010.00909.x · DOI
  9. Bannenberg, 2005, Molecular circuits of resolution: formation and actions of resolvins and protectins, J. Immunol., 174, 4345, 10.4049/jimmunol.174.7.4345 · DOI · Paper page
  10. Barden, 2016, n-3 Fatty acid supplementation and proresolving mediators of inflammation, Curr. Opin. Lipidol., 27, 26, 10.1097/MOL.0000000000000262 · DOI
  11. Barden, 2016, Specialised pro-resolving mediators of inflammation in inflammatory arthritis, Prostagl. Leukot. Essent. Fat. Acids, 107, 24, 10.1016/j.plefa.2016.03.004 · DOI
  12. Bisgaard, 2016, Fish oil-derived fatty acids in pregnancy and wheeze and asthma in offspring, N. Engl. J. Med., 375, 2530, 10.1056/NEJMoa1503734 · DOI · Paper page
  13. Bohr, 2013, Resolvin D2 prevents secondary thrombosis and necrosis in a mouse burn wound model, Wound Repair Regen., 21, 35, 10.1111/j.1524-475X.2012.00853.x · DOI
  14. Borges da Silva, 2015, Splenic macrophage subsets and their function during blood-borne infections, Front. Immunol., 6, 480, 10.3389/fimmu.2015.00480 · DOI · Paper page
  15. Borgeson, 2012, Resolution of inflammation: therapeutic potential of pro-resolving lipids in type 2 diabetes mellitus and associated renal complications, Front. Immunol., 3, 318, 10.3389/fimmu.2012.00318 · DOI
  16. Brasky, 2013, Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial, J. Natl. Cancer Inst., 105, 1132, 10.1093/jnci/djt174 · DOI · Paper page
  17. Buechler, 2017, Pro-resolving molecules-new approaches to treat sepsis?, Int. J. Mol. Sci., 18, 10.3390/ijms18030476 · DOI
  18. Calder, 2013, Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology?, Br. J. Clin. Pharmacol., 75, 645, 10.1111/j.1365-2125.2012.04374.x · DOI · Paper page
  19. Calder, 2006, Early nutrition and immunity - progress and perspectives, Br. J. Nutr., 96, 774
  20. Campbell, 2010, Resolvin E1-induced intestinal alkaline phosphatase promotes resolution of inflammation through LPS detoxification, Proc. Natl. Acad. Sci. U. S. A., 107, 14298, 10.1073/pnas.0914730107 · DOI
  21. Chattopadhyay, 2017, Resolvin D1 via prevention of ROS-mediated SHP2 inactivation protects endothelial adherens junction integrity and barrier function, Redox Biol., 12, 438, 10.1016/j.redox.2017.02.023 · DOI
  22. Chavan, 2017, Mechanisms and therapeutic relevance of neuro-immune communication, Immunity, 46, 927, 10.1016/j.immuni.2017.06.008 · DOI · Paper page
  23. Chiang, 2015, Identification of resolvin D2 receptor mediating resolution of infections and organ protection, J. Exp. Med., 212, 1203, 10.1084/jem.20150225 · DOI · Paper page
  24. Chiang, 2017, Novel resolvin D2 receptor Axis in infectious inflammation, J. Immunol., 198, 842, 10.4049/jimmunol.1601650 · DOI
  25. Chiang, 2017, Structural elucidation and physiologic functions of specialized pro-resolving mediators and their receptors, Mol. Asp. Med., 10.1016/j.mam.2017.03.005 · DOI · Paper page
  26. Chiurchiu, 2016, Proresolving lipid mediators resolvin D1, resolvin D2, and maresin 1 are critical in modulating T cell responses, Sci. Transl. Med., 8, 353ra111, 10.1126/scitranslmed.aaf7483 · DOI · Paper page
  27. Cianci, 2016, Human periodontal stem cells release specialized proresolving mediators and carry immunomodulatory and prohealing properties regulated by lipoxins, Stem Cells Transl. Med., 5, 20, 10.5966/sctm.2015-0163 · DOI
  28. Codagnone, 2017, Resolvin D1 enhances the resolution of lung inflammation caused by long-term Pseudomonas aeruginosa infection, Mucosal Immunol.
  29. Colas, 2014, Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue, Am. J. Physiol. Cell Physiol., 307, C39, 10.1152/ajpcell.00024.2014 · DOI · Paper page
  30. Cooray, 2013, Ligand-specific conformational change of the G-protein-coupled receptor ALX/FPR2 determines proresolving functional responses, Proc. Natl. Acad. Sci. U. S. A., 110, 18232, 10.1073/pnas.1308253110 · DOI · Paper page
  31. Dalli, 2014, Identification of sulfido-conjugated mediators that promote resolution of infection and organ protection, Proc. Natl. Acad. Sci. U. S. A., 111, E4753, 10.1073/pnas.1415006111 · DOI
  32. Dalli, 2015, Elucidation of novel 13-series resolvins that increase with atorvastatin and clear infections, Nat. Med., 21, 1071, 10.1038/nm.3911 · DOI · Paper page
  33. Dalli, 2017, Vagal regulation of group 3 innate lymphoid cells and the immunoresolvent PCTR1 controls infection resolution, Immunity, 46, 92, 10.1016/j.immuni.2016.12.009 · DOI
  34. Dalli, 2017, Human sepsis eicosanoid and proresolving lipid mediator temporal profiles: correlations with survival and clinical outcomes, Crit. Care Med., 45, 58, 10.1097/CCM.0000000000002014 · DOI · Paper page
  35. Dalli, 2013, Proresolving and tissue-protective actions of annexin a1-based cleavage-resistant peptides are mediated by formyl peptide receptor 2/lipoxin A4 receptor, J. Immunol., 190, 6478, 10.4049/jimmunol.1203000 · DOI
  36. Dalli, 2015, Novel proresolving and tissue regenerative resolvin and protectin sulfido-conjugated pathways, FASEB J., 29, 2120, 10.1096/fj.14-268441 · DOI
  37. Dalli, 2016, Identification and actions of a novel third maresin conjugate in tissue regeneration: MCTR3, PLoS One, 11, e0149319, 10.1371/journal.pone.0149319 · DOI
  38. Dalli, 2012, Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and pro-resolving mediators, Blood, 120, e60, 10.1182/blood-2012-04-423525 · DOI · Paper page
  39. Dalli, 2016, Maresin conjugates in tissue regeneration biosynthesis enzymes in human macrophages, Proc. Natl. Acad. Sci. U. S. A., 113, 12232, 10.1073/pnas.1607003113 · DOI
  40. Dawczynski, 2017, Docosahexaenoic acid in the treatment of rheumatoid arthritis: a double-blind, placebo-controlled, randomized cross-over study with microalgae vs. sunflower oil, Clin. Nutr.
  41. De Caterina, 2011, n-3 fatty acids in cardiovascular disease, N. Engl. J. Med., 364, 2439, 10.1056/NEJMra1008153 · DOI · Paper page
  42. de Paiva, 2012, Resolvin E1 (RX-10001) reduces corneal epithelial barrier disruption and protects against goblet cell loss in a murine model of dry eye, Cornea, 31, 1299, 10.1097/ICO.0b013e31823f789e · DOI
  43. Delano, 2016, The immune system's role in sepsis progression, resolution, and long-term outcome, Immunol. Rev., 274, 330, 10.1111/imr.12499 · DOI · Paper page
  44. Deng, 2014, Maresin biosynthesis and identification of maresin 2, a new anti-inflammatory and pro-resolving mediator from human macrophages, PLoS One, 9, e102362, 10.1371/journal.pone.0102362 · DOI
  45. Di Giuseppe, 2013, Long-term intake of dietary long-chain n-3 polyunsaturated fatty acids and risk of rheumatoid arthritis: a prospective cohort study of women, Ann. Rheum. Dis.
  46. Easley, 2016, AT-RvD1 combined with DEX is highly effective in treating TNF-alpha-mediated disruption of the salivary gland epithelium, Physiol. Rep., 4, 10.14814/phy2.12990 · DOI
  47. English, 2017, Identification and profiling of specialized pro-resolving mediators in human tears by lipid mediator metabolomics, Prostag. Leukot. Essent. Fat. Acids, 117, 17, 10.1016/j.plefa.2017.01.004 · DOI
  48. Enkhbaatar, 2016, Cellular therapy for sepsis: a new hope?, Crit. Care Med., 44, 2296, 10.1097/CCM.0000000000002147 · doi:10.1097/ccm.0000000000002147
  49. Epstein, 2016, Varying estimates of sepsis mortality using death certificates and administrative Codes–United States, 1999-2014, MMWR. Morb. Mortal. Wkly. Rep., 65, 342, 10.15585/mmwr.mm6513a2 · DOI
  50. Feng, 2012, Resolvin D1 reverses chronic pancreatitis-induced mechanical allodynia, phosphorylation of NMDA receptors,and cytokines expression in the thoracic spinal dorsal horn, BMC Gastroenterol., 12, 148, 10.1186/1471-230X-12-148 · DOI
  51. Fujieda, 2013, Inflammation and resolution are associated with upregulation of fatty acid beta-oxidation in Zymosan-induced peritonitis, PLoS One, 8, e66270, 10.1371/journal.pone.0066270 · DOI
  52. Gilbert, 2014, Resolvin D1, a metabolite of omega-3 polyunsaturated fatty acid, decreases post-myocardial infarct depression, Mar. Drugs, 12, 5396, 10.3390/md12115396 · DOI
  53. Hellmann, 2011, Resolvin D1 decreases adipose tissue macrophage accumulation and improves insulin sensitivity in obese-diabetic mice, FASEB J., 25, 2399, 10.1096/fj.10-178657 · DOI · Paper page
  54. Higgs, 1987, Pharmacokinetics of aspirin and salicylate in relation to inhibition of arachidonate cyclooxygenase and antiinflammatory activity, Proc. Natl. Acad. Sci. U. S. A., 84, 1417, 10.1073/pnas.84.5.1417 · DOI
  55. Hilberath, 2011, Resolution of Toll-like receptor 4-mediated acute lung injury is linked to eicosanoids and suppressor of cytokine signaling 3, FASEB J., 25, 1827, 10.1096/fj.10-169896 · DOI
  56. Hisada, 2009, Resolvin E1 as a novel agent for the treatment of asthma, Expert Opin. Ther. Targets, 13, 513, 10.1517/14728220902865622 · DOI
  57. Huang, 2017, Targeting the D Series resolvin receptor system for the treatment of osteoarthritis pain, Arthritis Rheumatol., 69, 996, 10.1002/art.40001 · DOI
  58. Huang, 2011, Enduring prevention and transient reduction of post-operative pain by intrathecal resolvin D1, Pain, 152, 557, 10.1016/j.pain.2010.11.021 · DOI
  59. Ishida, 2010, Resolvin E1, an endogenous lipid derived from eicosapentaenoic acid, prevents dextran sulfate sodium-induced colitis, Inflamm. Bowel Dis., 16, 87, 10.1002/ibd.21029 · DOI · Paper page
  60. Ishikawa, 2017, Rapid and sustained antidepressant effects of resolvin D1 and D2 in a chronic unpredictable stress model, Behav. Brain Res., 332, 233, 10.1016/j.bbr.2017.06.010 · DOI
  61. Isobe, 2012, Identification and structure determination of novel anti-inflammatory mediator resolvin E3, 17,18-dihydroxyeicosapentaenoic acid, J. Biol. Chem., 287, 10525, 10.1074/jbc.M112.340612 · DOI
  62. Isobe, 2012, Emerging roles of eosinophils and eosinophil-derived lipid mediators in the resolution of inflammation, Front. Immunol., 3, 270, 10.3389/fimmu.2012.00270 · DOI
  63. Janes, 2006, Data-driven modelling of signal-transduction networks, Nat. Rev. Mol. Cell Biol., 7, 820, 10.1038/nrm2041 · DOI · Paper page
  64. Jaudszus, 2013, Evaluation of suppressive and pro-resolving effects of EPA and DHA in human primary monocytes and T-helper cells, J. Lipid Res., 54, 923, 10.1194/jlr.P031260 · DOI
  65. Jin, 2009, Anti-angiogenesis effect of the novel anti-inflammatory and pro-resolving lipid mediators, Invest. Ophthalmol. Vis. Sci., 50, 4743, 10.1167/iovs.08-2462 · DOI
  66. Jo, 2016, Resolvin E1 inhibits substance P-Induced potentiation of TRPV1 in primary sensory neurons, Mediat. Inflamm., 2016, 5259321, 10.1155/2016/5259321 · DOI
  67. Jones, 2013, Maternal dietary omega-3 fatty acid intake increases resolvin and protectin levels in the rat placenta, J. Lipid Res., 54, 2247, 10.1194/jlr.M039842 · DOI
  68. Kasuga, 2008, Rapid appearance of resolvin precursors in inflammatory exudates: novel mechanisms in resolution, J. Immunol., 181, 8677, 10.4049/jimmunol.181.12.8677 · DOI
  69. Kenchegowda, 2013, Involvement of pigment epithelium-derived factor, docosahexaenoic acid and neuroprotectin D1 in corneal inflammation and nerve integrity after refractive surgery, Prostag. Leukot. Essent. Fat. Acids, 88, 27, 10.1016/j.plefa.2012.03.010 · DOI
  70. Keyes, 2010, Resolvin E1 protects the rat heart against reperfusion injury, Am. J. Physiol. Heart Circ. Physiol., 299, H153, 10.1152/ajpheart.01057.2009 · DOI · Paper page
  71. Kim, 2012, Omega-3 fatty acid-derived mediator, Resolvin E1, ameliorates 2,4-dinitrofluorobenzene-induced atopic dermatitis in NC/Nga mice, Int. Immunopharmacol., 14, 384, 10.1016/j.intimp.2012.08.005 · DOI
  72. Koltsida, 2013, Toll-like receptor 7 stimulates production of specialized pro-resolving lipid mediators and promotes resolution of airway inflammation, EMBO Mol. Med., 5, 762, 10.1002/emmm.201201891 · DOI
  73. Kosaraju, 2017, B cell activity is impaired in human and mouse obesity and is responsive to an essential fatty acid upon murine influenza infection, J. Immunol., 198, 4738, 10.4049/jimmunol.1601031 · DOI
  74. Krishnamoorthy, 2010, Resolvin D1 binds human phagocytes with evidence for pro-resolving receptors, Proc. Natl. Acad. Sci. U.S.A., 107, 1660, 10.1073/pnas.0907342107 · DOI · Paper page
  75. Krishnamoorthy, 2015, Cutting edge: maresin-1 engages regulatory T cells to limit type 2 innate lymphoid cell activation and promote resolution of lung inflammation, J. Immunol., 194, 863, 10.4049/jimmunol.1402534 · DOI · Paper page
  76. Lannan, 2017, Maresin 1 induces a novel pro-resolving phenotype in human platelets, J. Thromb. Haemost., 10.1111/jth.13620 · DOI
  77. Lee, 2012, Resolvins as new fascinating drug candidates for inflammatory diseases, Arch. Pharm. Res., 35, 3, 10.1007/s12272-012-0121-z · DOI
  78. Lee, 2015, Resolvin infectious inflammation by targeting the host response, N. Engl. J. Med., 373, 2183, 10.1056/NEJMcibr1511280 · DOI
  79. Lee, 2013, Resolvin D1 stimulates efferocytosis through p50/p50-mediated suppression of tumor necrosis factor-alpha expression, J. Cell Sci., 126, 4037
  80. Lee, 2017, NLRP3 inflammasome deficiency protects against microbial sepsis via increased lipoxin B4 synthesis, Am. J. Respir. Crit. Care Med., 10.1164/rccm.201604-0892OC · DOI
  81. Leslie, 2015, Inflammation's stop signals, Science, 347, 18, 10.1126/science.347.6217.18 · doi:10.1126/science.347.6217.18
  82. Levy, 2007, Protectin D1 is generated in asthma and dampens airway inflammation and hyper-responsiveness, J. Immunol., 178, 496, 10.4049/jimmunol.178.1.496 · DOI · Paper page
  83. Li, 2013, Resolvin D1 and aspirin-triggered resolvin D1 regulate histamine-stimulated conjunctival goblet cell secretion, Mucosal Immunol., 6, 1119, 10.1038/mi.2013.7 · DOI
  84. Li, 2010, Resolvin E1 improves tear production and decreases inflammation in a dry eye mouse model, J. Ocul. Pharmacol. Ther., 26, 431, 10.1089/jop.2010.0019 · DOI
  85. Liao, 2012, Resolvin D1 attenuates inflammation in lipopolysaccharide-induced acute lung injury through a process involving the PPARgamma/NF-kappaB pathway, Respir. Res., 13, 110, 10.1186/1465-9921-13-110 · DOI
  86. Libby, 2015, ALX-chemy: adding spice to the inflammatory soup of atherosclerosis, Cardiovasc. Res., 105, 3, 10.1093/cvr/cvu245 · DOI
  87. Lima-Garcia, 2011, The precursor of resolvin D series and aspirin-triggered resolvin D1 display anti-hyperalgesic properties in adjuvant-induced arthritis in rats, Br. J. Pharmacol., 164, 278, 10.1111/j.1476-5381.2011.01345.x · DOI
  88. Liu, 2012, Neuronal phagocytosis by inflammatory macrophages in ALS spinal cord: inhibition of inflammation by resolvin D1, Am. J. Neurodegener. Dis., 1, 60
  89. Lourdudoss, 2017, Dietary intake of polyunsaturated fatty acids and pain in spite of inflammatory control among methotrexate treated early rheumatoid arthritis patients, Arthritis Care Res. Hob.
  90. Lucas, 2014, Downregulation of Mcl-1 has anti-inflammatory pro-resolution effects and enhances bacterial clearance from the lung, Mucosal Immunol., 7, 857, 10.1038/mi.2013.102 · DOI
  91. Lukiw, 2005, A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease, J. Clin. Invest, 115, 2774, 10.1172/JCI25420 · DOI · Paper page
  92. Lund, 2010, Resolvin E1 reduces proinflammatory markers in human pancreatic islets in vitro, Exp. Clin. Endocrinol. Diabetes, 118, 237, 10.1055/s-0029-1241825 · doi:10.1055/s-0029-1241825
  93. Lundstrom, 2013, Lipid mediator serum profiles in asthmatics significantly shift following dietary supplementation with omega-3 fatty acids, Mol. Nutr. Food Res., 57, 1378, 10.1002/mnfr.201200827 · DOI
  94. Luo, 2016, Phagocyte respiratory burst activates macrophage erythropoietin signalling to promote acute inflammation resolution, Nat. Commun., 7, 12177, 10.1038/ncomms12177 · DOI
  95. Martinez-Fernandez, 2017, Maresin 1 improves insulin sensitivity and attenuates adipose tissue inflammation in ob/ob and diet-induced obese mice, FASEB J.
  96. Mas, 2016, A randomized controlled trial of the effects of n-3 fatty acids on resolvins in chronic kidney disease, Clin. Nutr., 35, 331, 10.1016/j.clnu.2015.04.004 · DOI
  97. Mebius, 2005, Structure and function of the spleen, Nat. Rev. Immunol., 5, 606, 10.1038/nri1669 · DOI · Paper page
  98. Miki, 2013, Lymphoid tissue phospholipase A2 group IID resolves contact hypersensitivity by driving antiinflammatory lipid mediators, J. Exp. Med., 210, 1217, 10.1084/jem.20121887 · DOI
  99. Miyahara, 2013, D-series resolvins attenuate vascular smooth muscle cell activation and neointimal hyperplasia following vascular injury, FASEB J., 27, 2220, 10.1096/fj.12-225615 · DOI
  100. Miyata, 2013, Dysregulated synthesis of protectin D1 in eosinophils from patients with severe asthma, J. Allergy Clin. Immunol., 131, 353, 10.1016/j.jaci.2012.07.048 · DOI
  101. Montero-Melendez, 2015, Biased agonism as a novel strategy to harness the proresolving properties of melanocortin receptors without eliciting melanogenic effects, J. Immunol., 194, 3381, 10.4049/jimmunol.1402645 · DOI
  102. Morris, 2010, Dichotomy in duration and severity of acute inflammatory responses in humans arising from differentially expressed proresolution pathways, Proc. Natl. Acad. Sci. U. S. A., 107, 8842, 10.1073/pnas.1000373107 · DOI
  103. Morris, 2010, Dichotomy in duration and severity of acute inflammatory responses in humans arising from differentially expressed proresolution pathways, Proc. Natl. Acad. Sci. U. S. A., 107, 8842, 10.1073/pnas.1000373107 · DOI
  104. Morris, 2009, Effects of low-dose aspirin on acute inflammatory responses in humans, J. Immunol., 183, 2089, 10.4049/jimmunol.0900477 · DOI · Paper page
  105. Mozurkewich, 2016, Pathway markers for pro-resolving lipid mediators in maternal and umbilical cord blood: a secondary Analysis of the mothers, Omega-3, and mental health study, Front. Pharmacol., 7, 274, 10.3389/fphar.2016.00274 · DOI
  106. Nathan, 2012, Fresh approaches to anti-infective therapies, Sci. Transl. Med., 4, 140sr142, 10.1126/scitranslmed.3003081 · DOI · Paper page
  107. Navarro-Xavier, 2010, A new strategy for the identification of novel molecules with targeted proresolution of inflammation properties, J. Immunol., 184, 1516, 10.4049/jimmunol.0902866 · DOI
  108. Nebert, 2017, Aryl hydrocarbon receptor (AHR): “pioneer member” of the basic-helix/loop/helix per-Arnt-sim (bHLH/PAS) family of “sensors” of foreign and endogenous signals, Prog. Lipid Res., 67, 38, 10.1016/j.plipres.2017.06.001 · DOI · Paper page
  109. Norling, 2016, Proresolving and cartilage-protective actions of resolvin D1 in inflammatory arthritis, JCI Insight, 1, e85922, 10.1172/jci.insight.85922 · DOI · Paper page
  110. Norling, 2013, The role of omega-3 derived resolvins in arthritis, Curr. Opin. Pharmacol., 13, 476, 10.1016/j.coph.2013.02.003 · DOI
  111. Norling, 2011, Cutting edge: humanized nano-proresolving medicines mimic inflammation-resolution and enhance wound healing, J. Immunol., 186, 5543, 10.4049/jimmunol.1003865 · DOI · Paper page
  112. Oh, 2011, Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation, J. Clin. Invest, 121, 569, 10.1172/JCI42545 · DOI · Paper page
  113. Palmer, 2011, 17(R)-Resolvin D1 differentially regulates TLR4-mediated responses of primary human macrophages to purified LPS and live E. coli, J. Leukoc. Biol., 90, 459, 10.1189/jlb.0311145 · DOI
  114. Park, 2015, Maresin 1 inhibits TRPV1 in temporomandibular joint-related trigeminal nociceptive neurons and TMJ inflammation-induced synaptic plasticity in the trigeminal nucleus, Mediat. Inflamm., 2015, 275126, 10.1155/2015/275126 · DOI
  115. Perretti, 2017, Immune resolution mechanisms in inflammatory arthritis, Nat. Rev. Rheumatol., 13, 87, 10.1038/nrrheum.2016.193 · DOI
  116. Pillai, 2012, Chemical mediators of inflammation and resolution in post-operative abdominal aortic aneurysm patients, Inflammation, 35, 98, 10.1007/s10753-011-9294-8 · DOI
  117. Poisson, 2015, Untargeted plasma metabolomics identifies endogenous metabolite with drug-like properties in chronic animal model of multiple sclerosis, J. Biol. Chem., 290, 30697, 10.1074/jbc.M115.679068 · DOI
  118. Polus, 2016, Omega-3 fatty acid supplementation influences the whole blood transcriptome in women with obesity, associated with pro-resolving lipid mediator production, Biochim. Biophys. Acta, 1861, 1746, 10.1016/j.bbalip.2016.08.005 · DOI
  119. Pope, 2016, D-series resolvins inhibit murine abdominal aortic aneurysm formation and increase M2 macrophage polarization, FASEB J., 30, 4192, 10.1096/fj.201600144RR · DOI
  120. Pruss, 2011, Non-resolving aspects of acute inflammation after spinal cord injury (SCI): indices and resolution plateau, Brain Pathol., 21, 652, 10.1111/j.1750-3639.2011.00488.x · DOI
  121. Psychogios, 2011, The human serum metabolome, PLoS One, 6, e16957, 10.1371/journal.pone.0016957 · DOI · Paper page
  122. Qu, 2012, Resolvins E1 and D1 inhibit interstitial fibrosis in the obstructed kidney via inhibition of local fibroblast proliferation, J. Pathol., 228, 506, 10.1002/path.4050 · DOI
  123. Rajasagi, 2017, Frontline Science: aspirin-triggered resolvin D1 controls herpes simplex virus-induced corneal immunopathology, J. Leukoc. Biol., 10.1189/jlb.3HI1216-511RR · DOI
  124. Rajasagi, 2011, Controlling herpes simplex virus-induced ocular inflammatory lesions with the lipid-derived mediator resolvin E1, J. Immunol., 186, 1735, 10.4049/jimmunol.1003456 · DOI
  125. Ramaswami, 2016, Fish oil supplementation in pregnancy, N. Engl. J. Med., 375, 2599, 10.1056/NEJMclde1614333 · DOI
  126. Ramon, 2016, The Protectin PCTR1 is produced by human M2 macrophages and enhances resolution of infectious inflammation, Am. J. Pathol., 186, 962, 10.1016/j.ajpath.2015.12.012 · DOI
  127. Ramsden, 2016, Breathing easier with fish oil - a new approach to preventing asthma?, N. Engl. J. Med., 375, 2596, 10.1056/NEJMe1611723 · doi:10.1056/nejme1611723
  128. Rathod, 2017, Accelerated resolution of inflammation underlies sex differences in inflammatory responses in humans, J. Clin. Invest, 127, 169, 10.1172/JCI89429 · DOI
  129. Rodriguez, 2015, First total synthesis of pro-resolving and tissue regenerative maresin sulfido-conjugates, Tetraahedron Lett., 56, 3936, 10.1016/j.tetlet.2015.04.131 · DOI
  130. Rodriguez, 2017, First total synthesis of pro-resolving and tissue-regenerative resolvin sulfido-conjugates, Tetrahedron Lett., 58, 1662, 10.1016/j.tetlet.2017.03.041 · DOI
  131. Rogerio, 2012, Resolvin D1 and aspirin-triggered resolvin D1 promote resolution of allergic airways responses, J. Immunol., 189, 1983, 10.4049/jimmunol.1101665 · DOI · Paper page
  132. Russell, 2014, The role of pro-resolution lipid mediators in infectious disease, Immunology, 141, 166, 10.1111/imm.12206 · DOI
  133. Samuelsson, 1983, Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation, Science, 220, 568, 10.1126/science.6301011 · DOI · Paper page
  134. Samuelsson, 1983, Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation, Science, 220, 568, 10.1126/science.6301011 · DOI · Paper page
  135. Samuelsson, 2012, Role of basic science in the development of new medicines: examples from the eicosanoid field, J. Biol. Chem., 287, 10070, 10.1074/jbc.X112.351437 · DOI
  136. Sanchez Alvarado, 2006, Planarian regeneration: its end is its beginning, Cell, 124, 241, 10.1016/j.cell.2006.01.012 · DOI
  137. Schwab, 2007, Resolvin E1 and protectin D1 activate inflammation-resolution programmes, Nature, 447, 869, 10.1038/nature05877 · DOI · Paper page
  138. Schwanke, 2016, EPA- and DHA-derived resolvins' actions in inflammatory bowel disease, Eur. J. Pharmacol., 785, 156, 10.1016/j.ejphar.2015.08.050 · DOI
  139. Seki, 2010, The anti-inflammatory and proresolving mediator resolvin E1 protects mice from bacterial pneumonia and acute lung injury, J. Immunol., 184, 836, 10.4049/jimmunol.0901809 · DOI · Paper page
  140. Serhan, 2004, A search for endogenous mechanisms of anti-inflammation uncovers novel chemical mediators: missing links to resolution, Histochem. Cell Biol., 122, 305, 10.1007/s00418-004-0695-8 · DOI
  141. Serhan, 2017, Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms, FASEB J., 10.1096/fj.201601222R · DOI · Paper page
  142. Serhan, 2012, Macrophage pro-resolving mediator maresin 1 stimulates tissue regeneration and controls pain, FASEB J., 26, 1755, 10.1096/fj.11-201442 · DOI · Paper page
  143. Serhan, 2011, Novel proresolving aspirin-triggered DHA pathway, Chem. Biol., 18, 976, 10.1016/j.chembiol.2011.06.008 · DOI
  144. Serhan, 2006, Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers: assignments of dihydroxy-containing docosatrienes, J. Immunol., 176, 1848, 10.4049/jimmunol.176.3.1848 · DOI · Paper page
  145. Serhan, 2002, Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter pro-inflammation signals, J. Exp. Med., 196, 1025, 10.1084/jem.20020760 · DOI · Paper page
  146. Serhan, 2011, Novel anti-inflammatory - pro-resolving mediators and their receptors, Curr. Top. Med. Chem., 11, 629, 10.2174/1568026611109060629 · DOI · Paper page
  147. Settimio, 2012, Resolvin D1 reduces the immunoinflammatory response of the rat eye following uveitis, Mediat. Inflamm., 2012, 318621, 10.1155/2012/318621 · DOI
  148. Sheets, 2010, Neuroprotectin D1 attenuates laser-induced choroidal neovascularization in mouse, Mol. Vis., 16, 320
  149. Shimizu, 2009, Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation, Annu. Rev. Pharmacol. Toxicol., 49, 123, 10.1146/annurev.pharmtox.011008.145616 · DOI · Paper page
  150. Tabas, 2013, Anti-inflammatory therapy in chronic disease: challenges and opportunities, Science, 339, 166, 10.1126/science.1230720 · DOI · Paper page
  151. Takano, 1998, Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15-epi-lipoxin A4 and novel lipoxin B4 stable analogues, J. Clin. Invest, 101, 819, 10.1172/JCI1578 · DOI
  152. Tanaka, 2017, Eicosapentaenoic acid-enriched high-density lipoproteins exhibit anti-atherogenic properties, Circ. J.
  153. Tang, 2017, Maresin 1 mitigates high glucose-induced mouse glomerular mesangial cell injury by inhibiting inflammation and fibrosis, Mediat. Inflamm., 2017, 2438247, 10.1155/2017/2438247 · DOI
  154. Tang, 2013, Proresolution therapy for the treatment of delayed healing of diabetic wounds, Diabetes, 62, 618, 10.2337/db12-0684 · DOI
  155. Terrando, 2013, Aspirin-triggered resolvin D1 prevents surgery-induced cognitive decline, FASEB J., 27, 3564, 10.1096/fj.13-230276 · DOI
  156. Tjonahen, 2006, Resolvin E2: identification and anti-inflammatory actions: pivotal role of human 5-lipoxygenase in resolvin E series biosynthesis, Chem. Biol., 13, 1193, 10.1016/j.chembiol.2006.09.011 · DOI · Paper page
  157. Uno, 2016, Immunonutrition suppresses acute inflammatory responses through modulation of resolvin E1 in patients undergoing major hepatobiliary resection, Surgery, 160, 228, 10.1016/j.surg.2016.01.019 · DOI
  158. Vassiliou, 2008, Bone marrow-derived dendritic cells generated in the presence of resolvin E1 induce apoptosis of activated CD4+ T cells, J. Immunol., 181, 4534, 10.4049/jimmunol.181.7.4534 · DOI
  159. Wan, 2011, Leukotriene B4/antimicrobial peptide LL-37 proinflammatory circuits are mediated by BLT1 and FPR2/ALX and are counter-regulated by lipoxin A4 and resolvin E1, FASEB J., 25, 1697, 10.1096/fj.10-175687 · DOI
  160. Wang, 2015, Maresin 1 biosynthesis and proresolving anti-infective functions with human-localized aggressive periodontitis leukocytes, Infect. Immun., 84, 658, 10.1128/IAI.01131-15 · DOI · Paper page
  161. Wang, 2017, Prevention of chronic post-thoracotomy pain in rats by intrathecal resolvin D1 and D2: effectiveness of perioperative and delayed drug delivery, J. Pain, 18, 535
  162. Ward, 2012, A historical perspective on sepsis, Am. J. Pathol., 181, 2, 10.1016/j.ajpath.2012.05.003 · DOI
  163. Wei, 2017, The role of pro-resolving lipid mediators in ocular diseases, Mol. Asp. Med., 10.1016/j.mam.2017.03.006 · DOI
  164. Wu, 2013, Efficacy and safety of 15(r/S)-methyl-lipoxin A(4) in topical treatment of infantile eczema, Br. J. Dermatol, 168, 172, 10.1111/j.1365-2133.2012.11177.x · DOI
  165. Xu, 2010, Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions, Nat. Med., 16, 592, 10.1038/nm.2123 · DOI · Paper page
  166. Xu, 2013, Resolvin E1 inhibits neuropathic pain and spinal cord microglial activation following peripheral nerve injury, J. Neuroimmune Pharmacol., 8, 37, 10.1007/s11481-012-9394-8 · DOI
  167. Yu, 2015, Inverse relationship between serum lipoxin A4 level and the risk of metabolic syndrome in a middle-aged Chinese population, PLoS One, 10, e0142848, 10.1371/journal.pone.0142848 · DOI

Cited by

See all 245

Metadata

Authors
Serhan, C. N., Chiang, N., & Dalli, J.
Venue
Molecular Aspects of Medicine
Publisher
Elsevier BV
Published
2018-12
Volume
64
Pages
1-17
ISSN
0098-2997 (ISSN-L)
DOI
10.1016/j.mam.2017.08.002
OpenAlex
W2752260686
Cited by
245
References
29
FWCI
17.45
Type
journal article
Language
en
Open access
bronze
Licence
Funders
  • Wellcome Trust and the Royal Society (107613/Z/15/Z)
  • European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (677542)
  • Barts Charity (MGU0343)
  • National Institutes of Health USA (R01GM38765, P01GM095467)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: New pro-resolving n-3 mediators bridge resolution of infectious inflammation to tissue regeneration. https://app.cochat.ai/papers/10.1016/j.mam.2017.08.002
The paper
Serhan, C. N., Chiang, N., & Dalli, J. (2018). New pro-resolving n-3 mediators bridge resolution of infectious inflammation to tissue regeneration. Molecular Aspects of Medicine. https://doi.org/10.1016/j.mam.2017.08.002

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.